SLC16A11 Expression via mTOR Inhibitors for Type 2 Diabetes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Type 2 diabetes disproportionately affects Mexican and Latin American populations, with limited effective methods for treatment and prevention, particularly in these demographics.
Innovation Solution
The use of mechanistic target of rapamycin (mTOR) inhibitors, such as KU-0063794 and AZD-8055, or checkpoint kinase (CHK) inhibitors, such as AZD-7762, to increase the expression of the SLC16A11 polypeptide in diabetic subjects carrying a SLC16A11 risk haplotype, thereby enhancing the activity or level of the wild-type SLC16A11 protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mTOR inhibitors or CHK inhibitors are used to increase SLC16A11 expression, then the therapeutic effect on type 2 diabetes is improved, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent identifies subjects carrying the SLC16A11 risk haplotype before treatment initiation through genetic testing. This preliminary identification allows for targeted therapy assignment, ensuring that only appropriate candidates receive the complex mTOR or CHK inhibitor treatment, thereby improving therapeutic reliability while managing treatment complexity through selective application
Solution Approach 2:
The treatment approach is tailored to specific genetic subpopulations (those with the SLC16A11 risk haplotype) rather than applying a uniform treatment to all type 2 diabetes patients. This localized treatment strategy improves efficacy for the target group while reducing unnecessary exposure to complex treatments for non-responders
2Measurement precision
If genetic testing for SLC16A11 risk haplotype is performed to identify suitable subjects, then treatment precision is improved, but the cost and time of diagnosis increase
Solution Approach 1:
Genetic testing for the SLC16A11 risk haplotype is performed as a preliminary screening step before initiating treatment. This advance identification of suitable candidates ensures that only those who will benefit from the complex mTOR or CHK inhibitor therapy undergo the full diagnostic and treatment process, improving overall diagnostic precision while managing time loss through targeted testing
Solution Approach 2:
The SLC16A11 genetic marker serves as an intermediary that links the disease state (type 2 diabetes) with the appropriate treatment response. By testing for this intermediate genetic marker, the system achieves high diagnostic precision in identifying who will respond to treatment without requiring complex functional assays that would take longer
Data Source
Figure 1A
Figure 1B
Figure 2A-1~2A-2
AI summary
The invention features compositions and methods that are useful for increasing the level or activity of SLC16A11 in a subject, there by treating or preventing type 2 diabetes in the subject.